Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment

The goal of this study was to assess the antitumor efficacy and safety of lobaplatin-based regimens as the second line of treatment in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes, compared with that of cisplatin-based regimens. During August 2012 to April 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhipeng, Xu, Lei, Wang, Han, Li, Zhenzhi, Lu, Lu, Li, Xiaojia, Zhang, Qingyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087814/
https://www.ncbi.nlm.nih.gov/pubmed/30108440
http://dx.doi.org/10.1016/j.sjbs.2018.01.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087814/
https://www.ncbi.nlm.nih.gov/pubmed/30108440
http://dx.doi.org/10.1016/j.sjbs.2018.01.011

Ejemplares similares